AZNAstraZenecaSigning up patients
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric · Esophagogastric Junction
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 140 (planned)
- Started
- Oct 9, 2026
- Main results expected
- Nov 1, 2029
- Fully finished
- Nov 1, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To compare Arm A relative to Arm B on pCR rate
Measured over: Up to 24 months after the last participant is randomized
Changes Tremor has spotted
Status changed: Not started yet → Signing up patients. Usually normal progress.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · status_changed · overall_status
old: "NOT_YET_RECRUITING"
new: "RECRUITING"
Trial ID NCT07877818 · record last updated 2026-11-06 · checked 2026-11-09 15:47 UTC